LILRA4 Biologics Sequence Review Report 2026: Leukocyte immunoglobulin-like receptor subfamily A member 4 Similarity and Patent-Risk Signals

This LILRA4 Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It turns patent-scale sequence search, sequence retrieval, pairwise alignment and target evidence into a reproducible diligence narrative. Explore the PatSnap MCP servers used in this report.

Review date: 5 August 2026. This report supports R&D, competitive-intelligence and IP triage. It is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement, and a no-hit or low-hit result does not establish clearance.

Executive sequence-risk thesis

LILRA4 is a reviewed human protein asset represented by UniProt entry P59901. The reference sequence contains 499 amino acids and is annotated as Leukocyte immunoglobulin-like receptor subfamily A member 4. PatSnap’s patent-scale screen returned 200 matching records in the configured result universe. The leading reviewed hit showed 100.00% query identity across 499/499, with the database claim annotation recorded as Yes.

The resulting screen is classified as elevated diligence priority. That label prioritizes diligence; it does not classify the asset as blocked, available or unique. Whole-protein identity can be driven by conserved domains, common signal peptides, transmembrane regions or endogenous human sequence. Patent relevance depends on whether live claims cover the complete sequence, a fragment, an engineered variant, an antibody recognizing the target, a use, or a functional genus.

Why this protein is a biologics-relevant review subject

Leukocyte immunoglobulin-like receptor subfamily A member 4 is a traceable human protein sequence suitable for systematic similarity screening. For biologics teams, the sequence can matter in several distinct ways: it may be the administered protein, an extracellular target, an antigen used to raise antibodies, a receptor domain incorporated into a fusion, or a reference against which engineered variants are defined. Those possibilities produce different patent questions even when they share the same gene symbol.

This report therefore separates sequence proximity from legal scope. A close patent-sequence match can identify families worth reading, yet naturally occurring human protein sequence is not itself a conclusion about enforceable rights. Conversely, engineered substitutions, truncations, Fc fusions, linkers, glycosylation-site changes or epitope-defined claims may be commercially important even when the full-length reference is not reproduced verbatim.

Biology Modality MCP evidence workflow

The workflow began with ls_sequence_search_submit against ALLPATENT protein records and used ls_sequence_search_get_results to retrieve the leading evidence. ls_sequence_fetch resolved the selected patent-sequence record, and ls_sequence_alignment performed a PSA comparison to the reviewed UniProt query. Finally, ls_antibody_antigen_search tested target-linked antibody evidence and ls_patent_sequence_fetch retrieved sequences from a resolved patent record where available.

Similarity-search readout

The leading result was evaluated under a supplementary sensitivity search using 50–100% identity and 50–100% query coverage. It reported 499/499 identical positions, query coverage 499/499, subject coverage 499/499, E-value 0 and 0/499 gaps. The database marked the record as Yes for the claim annotation field.

The strict primary window did not yield a usable alignment within the initial service run, so this report also records a broader sensitivity screen. The broader result is explicitly secondary evidence and should not be compared directly with a strict-window hit without noting the threshold change.

The raw count of 200 records should not be read as the number of independent inventions. One sequence can appear in applications, grants, continuations, divisionals and multiple jurisdictions. It can also recur as a reference, antigen, control or prior-art comparator. Family consolidation by earliest priority, applicant, simple family and legal status is therefore essential before ranking competitive risk.

Sequence fetch and pairwise alignment

ls_sequence_fetch resolved sequence number 125647493 with a length of 499 aa. The fetched record was then supplied to ls_sequence_alignment for pairwise comparison with the reviewed LILRA4 sequence.

The PSA returned 1 alignment block(s). Reviewers should map mismatches to functional domains, extracellular segments, transmembrane regions, cleavage sites and engineered junctions. A concentrated change at a binding interface can matter more than a similar number of substitutions distributed across a nonfunctional region.

Antibody–antigen and patent-sequence evidence

The target-name query returned 126 antibody–antigen records. The leading record was US11072652B2, “ILT7 binding molecules and methods of using the same”. These records support target-context review, but they can describe research antibodies, comparators, parental molecules or constructs that do not correspond to the reviewed therapeutic asset.

Using the patent identifier resolved from the leading target record, ls_patent_sequence_fetch returned 141 associated patent sequences. The listing may include antigens, antibodies, fragments, controls, primers and manufacturing elements; each sequence number must be interpreted against the specification and claims.

Target-level evidence complements sequence similarity because biologics patents often define inventions through binding, epitope, function, disease use or combinations rather than an exact full-length target sequence. The strongest review links the returned sequence to a patent family, verifies the role of the sequence in the specification, and then reads live claims in the jurisdictions relevant to development or commercialization.

Patent-risk interpretation

Diligence actions

1. Confirm the exact therapeutic or experimental construct, including isoform, truncation, signal peptide, tags, linkers and fusion partners.
2. Cluster high-ranking sequence records by patent family and earliest priority date rather than counting publications.
3. Retrieve the underlying sequence listings and confirm the biological role of each selected sequence number.
4. Map alignment differences to extracellular domains, binding interfaces, catalytic motifs and engineered junctions.
5. Search LILRA4, Leukocyte immunoglobulin-like receptor subfamily A member 4 and known aliases in target, antibody, claim and assignee contexts.
6. Build jurisdiction-specific claim charts for live families and document licenses or collaboration rights.
7. Rerun the Biology Modality MCP workflow at the transaction or development decision date because database and legal-status coverage changes.

Bottom line

LILRA4 produced a traceable sequence-search result with 100.00% leading identity, 499/499 query coverage, 1 PSA block(s), 126 target-linked antibody records and 141 directly fetched patent sequences. Together, these signals support elevated diligence priority and a prioritized family-and-claim review. They do not support a binary clearance or infringement statement.

Explore PatSnap Open Platform MCP Servers to produce sequence similarity and patent-risk reports for antibodies, proteins, peptides and nucleic-acid assets.

Sources and methodology notes

Reference sequence metadata: reviewed human UniProt entry P59901. Patent-scale similarity, sequence detail, PSA, patent-sequence and antibody–antigen evidence was retrieved through PatSnap Biology Modality MCP on 5 August 2026. Results are bounded by the configured query, thresholds, aliases, task limits and database coverage; rerun at the decision date.